Menu
Recruiting NCT06113185

Psychometric Properties of Pain Scale in Low Back Pain

Observational Chronic Low Back Pain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: survey.
Who it may be relevant to
Registry conditions: Chronic Low Back Pain. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Turkish Psychometric Properties of Pain Behavior Scale in Patients With Chronic Low Back Pain

Overview

The aim of this study was to examine the Turkish validity of the Pain Behavior Scale in a population with chronic non-specific low back pain and to examine both intra-rater and inter-rater reliability. In addition, since this test package includes a series of functional activities, it is aimed to assess pain behaviors during functional movement in this population and to verify the test-retest reliability of physical performance tests.

Detailed description

To assess the extent to which individuals with chronic low back pain are affected during functional task performance, the presence or absence of pain behaviors and the severity of observed pain behavior should be considered. The Pain Behavior Scale has potential clinical application both for assessing pain behaviors during regular physical examination and for measuring the presence and severity of pain behaviors during functional movement. There is no similar assessment tool that offers all of these simultaneously. Therefore, this study aimed to examine the Turkish validity of the Pain Behavior Scale in a population with chronic non-specific low back pain and to test its intra- and inter-rater reliability.

Interventions

  • Other survey
    Demographic and clinical information of the participants will be recorded using a standardized form. The cognitive status of the patient will be evaluated according to the answers to the questions asked to the patient during the questioning of demographic data and reading and signing the consent form. The participants will be asked to complete a series of questionnaires to assess pain intensity and characteristics, pain-related functional disability, and pain-related fear-avoidance behavior. To

Primary outcome measures

  • Pain Behavior Scale [Time frame: At the beginning of the study and up to 1 weeks]
  • Visual Analog Scale [Time frame: At the beginning of the study]
  • McGill Pain Questionnaire-Short Form [Time frame: At the beginning of the study]
Secondary outcome measures (2)
  • Oswestry Disability Index [Time frame: At the beginning of the study]
  • Fear-Avoidance Beliefs Questionnaire [Time frame: At the beginning of the study]

Eligibility criteria

Inclusion criteria

  • Non-specific low back pain for more than three months
  • Being between the ages of 18-55
  • Adequate cognitive functions (reading, writing, recall, orientation, language)

Exclusion criteria

  • Presence of a serious underlying pathology (e.g. cancer, infection or cauda equina syndrome)
  • Presence of spinal stenosis
  • Presence of signs of radiculopathy (presence of neural symptoms such as pain radiating to the lower extremities, weakness, numbness and tingling sensation)
  • Presence of fracture or surgical history in the relevant area
  • Presence of rheumatic disease history
  • Presence of pregnancy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Turkey (Türkiye) · 1 center
  • Acıbadem Health Group — Istanbul

Identifiers

NCT: NCT06113185 · 2023-15/518

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗